Canadian Drug Companies

[Arctec]

Liponex shares jump


Tuesday, January 02, 2007

TORONTO — Shares in Ottawa-based drug developer Liponex Inc. were jolted upward by more than half to a new high Tuesday on speculation about its treatment to raise levels of so-called good cholesterol.

Hopes rose for Liponex's CRD5, a drug derived from soybeans and intended to increase concentrations of high-density lipoproteins in the blood, after Pfizer Inc. terminated work in early December on its torcetrapib cardiovascular drug following an elevated death rate among patients receiving it.

Liponex shares traded Tuesday morning as high as $2.45, jumping 91 cents on the TSX session, after having risen steadily from 95 cents before the Pfizer announcement.

CRD5 is in a Phase 1-2 trial on 50 heart patients in Ottawa, after an initial test showed 20 per cent increases in HDL with “no significant adverse events.”

Results of the new trial are expected early this year.

[originunknown]

ok thanks Onthego!

[Onthego]

Beats me. I am not trading until after the US election. Not a good time for me.

[originunknown]

Has IEX.tse reached bottom support at .20?

[Onthego]

Good idea, Thanks

[PerfectSage]

Hi otg

Right now the long term for the markets is still bullish, but the intermediate term trend has turned bearish.

Don't forget, October is the month long term bull & bear markets start. The yield curve is back to normal after being flat for a while.

Watch the yield curve, if it goes inverted this summer, there's going to be a bearrorist attack on the markets in the fall. lol

http://stockcharts.com/charts/YieldCurve.html

Watch the nasdaq chart too. The nasdaq while be the first index to break down to 52 week lows.

The naz started hitting 52 week highs for the first time in Q2/2003, looks like it hit 52 week highs in Aug 2004 a little bit, and has continued hitting 52 week highs since.

[Onthego]

Just the regular doldrums. The charts need a break before the fall run - cheers and Happy Rading..

[PerfectSage]

OTG Big bad bear in 2006??????????

[Onthego]

VAS-T Sedar - 2 reports plus NR 84m at 2.23

NB: This is just a portion of the release.

Vasogen loss stays flat at $19.3-million in Q1


2006-04-17 17:35 ET - News Release

Mr. Terrance Gregg reports

VASOGEN ANNOUNCES FIRST QUARTER 2006 RESULTS

Vasogen Inc. today released the results of operations for the three months ended Feb. 28, 2006.

At Feb. 28, 2006, the company's cash and cash equivalents, restricted cash and marketable securities held to maturity totalled $61.0-million, compared with $85.2-million at Nov. 30, 2005.

The company incurred a net loss for the three months ended Feb. 28, 2006, of $19.3-million, or 23 cents per common share, compared with a net loss of $19.9-million, or 27 cents per common share for the similar period in 2005. The loss has decreased as a result of a reduction in the costs associated with the company's phase III clinical programs and has been partially offset by expenses associated with the senior convertible notes. The difference between cash used in operations and the company's accounting loss includes such non-cash items as stock option grant expense, amortization expense, accretion and amortization of costs associated with the senior convertible notes payable, offset by payment of accrued expenses related to the company's phase III clinical trials.

For the three months ended Feb. 28, 2006, research and development expenditures decreased to $11.4-million from $16.8-million for the same period in 2005. The majority of the decrease in the company's research and development expense for the three months ended Feb. 28, 2006, when compared with the same period in 2005, resulted from a significant reduction in the clinical trial activities relating to the company's phase III programs.

General and administrative expenditures were $4.9-million for the three months ended Feb. 28, 2006, compared with $5.4-million for the same period in 2005.

Highlights


During the quarter, final patient assessments were completed in the 2,400-patient multinational pivotal phase III Acclaim trial of patients with advanced chronic heart failure. The Acclaim trial is designed to definitively assess the impact of the company's Celacade technology on reducing the risk of death and cardiovascular hospitalization in patients with advanced chronic heart failure. Based on the company's current timeline projections for completing the processes necessary to lock the Acclaim database, the company expects to report the initial results from this trial in the first half of 2006.


In March, 2006, the results of the Simpadico trial were presented at a late-breaking clinical trial session of the 55th Annual Scientific Session of the American College of Cardiology in Atlanta. While the Simpadico study did not reach the primary end point of change in maximal treadmill walking distance, therapy using the company's Celacade technology significantly reduced high-sensitivity C-reactive protein, a prespecified end point and a widely recognized marker of systemic inflammation associated with increased cardiovascular risk, including heart failure, stroke and heart attack. Therapy using the company's Celacade technology was also shown to significantly reduce the number of patients progressing to critical limb ischemia, a condition manifested by sharply diminished blood flow to the legs often resulting in the need for amputation. Exploratory analyses of the per-protocol population also showed improvements in certain quality-of-life measures and a statistically significant improvement in ankle-brachial index (measure of change in blood flow to the legs) at 26 weeks in the Celacade group.


On March 22, 2006, following the company's annual meeting of shareholders, Terrance H. Gregg succeeded William R. Grant as chairman of the company's board of directors. Mr. Gregg, who joined Vasogen's board of directors in 1999, has been vice-chairman since November, 2005, and has served as the chair of the compensation, nominating and corporate governance committee of the board for the past several years. Mr. Gregg's extensive experience in the health care sector includes his role as president and chief operating officer of MiniMed Inc., where he successfully transformed the company from a development-stage therapeutic device-company into a global leader in diabetes management systems. In 2001, Medtronic acquired MiniMed for $3.4-billion (U.S.). William R. Grant, who has served as Vasogen's chairman for the last five years, will remain a director on Vasogen's board.


The company also announced the appointment of Ronald M. Cresswell, PhD, hon. DSc, FRSE, former senior vice-president and chief scientific officer of Warner-Lambert, and Calvin R. Stiller, CM, O.ONT, MD, FRCP (C), co-founder and former chairman/chief executive officer of the Canadian Medical Discoveries Fund, to the company's board of directors during the quarter. Both Dr. Cresswell and Dr. Stiller have considerable experience directing the research, development and business initiatives of companies commercializing products for the health care industry. Dr. Cresswell has over 30 years of research and commercial development experience in cardiovascular and other important therapeutic areas and his vision and leadership in the development of Lipitor was instrumental in the product's ultimate success. Dr. Stiller was principal investigator of the Canadian multicentre study that established the importance of cyclosporine and led to its worldwide use as first-line therapy for transplant rejection.

As previously announced, a conference call and slide presentation will be conducted on April 18, 2006, at 8:30 a.m. Eastern Time. The slide presentation may be viewed at Vasogen's website, and the conference call may be accessed by calling 416-695-6622 or 1-800-769-8320, 10 minutes prior to the call. An audio webcast of the event will also be available at Vasogen's website. A rebroadcast of the conference call may be accessed by calling 1-800-293-5765, pin code 8019, and will also be available at Vasogen's website.

[Onthego]

MPH-T NR 80m at 2.00

Globe/DJ say Medicure beats hopeful on phase III study


2006-04-13 06:55 ET - In the News

The Globe and Mail reports in its Thursday, April 13, edition that Medicure is moving forward with a single confirmatory phase III study to gain approval for its MC-1 product to reduce cardiovascular events in patients undergoing coronary artery bypass graft surgery. A Dow Jones dispatch to The Globe reports the company said MC-1 has received a fast-track designation from the United Sates Food and Drug Administration. Introduction of the latest study is targeted for the second half of 2006. Medicure stock climbed 22 cents to close at $2. Medicure trades on the Toronto Stock Exchange. The stock has a 52-week trading range of $2.37 to 72 cents. National Bank Financial analyst Andre Uddin rated the stock "outperform" in The Globe on Sept. 15. He gave the stock a 12-month target price of $3.25. The stock has since climbed 82 cents. At the time Medicure president Albert Friesen said there was "extensive interest" by potential drug company partners. The Globe reported on Dec. 12 that analysts were predicting the biotech industry was turning the corner. Medicure stock has since advanced 47 cents. A $1,000 investment on Dec. 12 would now be worth $1,886.79.

[Onthego]

DDS-T NR today 43m at 8.98

Globe says Labopharm's tramadol looking good


2006-04-13 06:28 ET - In the News

The Globe and Mail reports in its Thursday edition that Labopharm said Wednesday its once-daily formulation of the tramadol painkiller did well in a phase III clinical trial. The Globe's Leonard Zehr writes the stage is set for regulatory approval of the drug in the U.S. on Sept. 28. Labopharm stock jumped 56 cents to close Wednesday in Toronto at $8.98. The stock hit an intraday high of $9.30. "We are extremely pleased with these results," said chief executive officer James Howard-Tripp. "This data enhances our NDA." The latest results will help bolster Labopharm's new drug application for the drug in the United States. The study compared the safety and effectiveness of the drug versus placebo over a 12-week period in patients diagnosed with moderate to severe pain from osteoarthritis of the knee. Merrill Lynch predicts Labopharm will turn the corner and become profitable for the first time in 2007, thanks to tramadol driving revenue to $90-million from $30-million this year. Labopharm has regulatory approval to sell its once-daily tramadol in the European Union. Labopharm's medication was also accepted for review by the U.S. Food and Drug Administration last November.

[Onthego]

QLT-T NR today 91m at 8.64

Globe says QLT cuts out annual report to save money


2006-04-12 08:41 ET - In the News

The Globe and Mail reports in its Wednesday edition in a move to reduce costs, QLT is not producing an annual report for 2005. The Globe's Leonard Zehr writes the move comes in a letter to shareholders from president and chief executive officer Robert Butchofsky. Instead, the drug developer will limit its annual reporting to a 10-K filing with securities regulators. The cost of design, print and mail for the annual report averages about $250,000. In the information circular for the annual meeting on May 9, the company said Mr. Butchofsky is paid a base salary of $520,000 (U.S.) a year. As of last September, when he was appointed interim CEO, replacing Paul Hastings. Mr. Hastings's salary in 2005 was $517,407 (U.S.). He did not receive a bonus but his severance payments will total about $2.9-million. QLT shares rose two cents Tuesday to $8.64 on the Toronto Stock Exchange

[Onthego]

MPH-T NR today 79m at 1.78

Medicure plans MC-1 phase III study


2006-04-12 08:26 ET - News Release

Mr. Derek Reimer reports

MEDICURE REPORTS ON MEND-CABG END OF PHASE II MEETING WITH THE FDA

Based on the positive phase II MEND-CABG study and a recent end of phase II meeting with the U.S. Food and Drug Administration, Medicure Inc. plans to proceed with a single confirmatory phase III study to gain approval for MC-1 in the reduction of cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery. MC-1 has received a fast-track designation from the FDA.

Based on the end of phase II meeting, Medicure plans to use a composite of cardiovascular death and non-fatal myocardial infarction (primary definition peak CK-MB greater than or equal to 100 nanograms per millilitre) at postoperative day 30 as the primary end point for the phase III study. Initiation of this study is targeted for the second half of calendar 2006.

"We are extremely pleased with the outcome of the end of phase II meeting with the FDA. A single confirmatory study provides Medicure the most efficient and affordable path for MC-1's phase III development, and is a valuable asset in our partnership negotiations," commented Medicure's president and chief executive officer, Albert D. Friesen, PhD. "MC-1 has the opportunity to be the first product indicated to reduce cardiovascular events associated with ischemia and/or ischemic reperfusion injury in CABG patients, targeting a significant unmet medical need. We look forward to working with the FDA in expediting the development of MC-1."

MC-1 is a small molecule that reduces the amount of damage to the heart following ischemia and/or ischemic reperfusion injury. Studies with MC-1 suggest that it does this by protecting cardiomyocytes (heart muscle cells). Since cardiomyocytes are essential for normal heart function and do not regenerate themselves following an ischemic event, their preservation is key to minimizing ischemic damage and maintaining proper heart function. MC-1's cardioprotective properties have been demonstrated in the phase II MEND-1 study in patients undergoing percutaneous coronary interventions and the phase II MEND-CABG study in patients undergoing CABG surgery.

We seek Safe Harbor.

[Onthego]

DDS-T NR today 43m at 8.42

Labopharm gets significant statistics in tramadol trial


2006-04-12 07:17 ET - News Release

Mr. James Howard-Tripp reports

LABOPHARM REPORTS POSITIVE RESULTS FOR PHASE III STUDY ON ONCE-DAILY TRAMADOL - RESULTS TO BE ADDED TO NDA WITH PDUFA DATE OF SEPTEMBER 28, 2006

Labopharm Inc.'s recently completed multicentre phase III clinical trial (MDT3-005) for its once-daily formulation of tramadol achieved statistical significance for the primary end point.

"We are extremely pleased with these results. This data enhances our NDA currently being reviewed by the Food and Drug Administration," said James R. Howard-Tripp, president and chief executive officer, Labopharm.

The results of the study will be added to the company's new drug application (NDA) for once-daily tramadol in the United States, which is currently under review by the Food and Drug Administration (FDA). Based on discussions with the FDA, the company plans to submit the data on a timely basis such that the action date under the Prescription Drug User Fee Act (PDUFA) remains Sept. 28, 2006.

Results of the study

The randomized, double-blind, multicentre parallel study conducted under a special protocol assessment with the FDA, compared the safety and efficacy of Labopharm's once-daily formulation of tramadol to placebo over a 12-week period. Enrolment in the trial consisted of patients diagnosed with moderate to severe pain associated with osteoarthritis of the knee. Patients were randomized to treatment with Labopharm's once-daily tramadol or placebo and underwent double-blind titration to an optimal dose of either 200 or 300 milligrams. The optimal dose for each patient, which was maintained for a period of 12 weeks, was selected based on the effectiveness of pain relief and the tolerability of adverse events. Approximately 1,000 patients were enrolled in this trial.

The primary end point of the study was to compare baseline pain intensity with pain intensity at the end of the study period as measured by the 11-point pain intensity numerical rating score (PI-NRS) in the once-daily tramadol group versus the placebo group. Statistical significance was achieved for the primary end point (p value of 0.0157) and was maintained under additional methods of analysis. The dropout rate was comparable with that of the company's European phase III trial (MDT3-001). The incidence of adverse events was lower than in study MDT3-001, and similar to the previous two United States phase III clinical trials (MDT3-002 and MDT3-003).

We seek Safe Harbor.

[Onthego]

CVQ-T NR today 102m at 3.00

Van Sun says CV Technologies gets case of reticence


2006-04-12 09:28 ET - In the News

The Vancouver Sun reports in its Wednesday edition in February, The Sun questioned studies that support the medical value of CV Technologies' COLD-fX product. The Sun's David Baines writes that chief executive officer Jacqueline Shan then launched a counteroffensive. Mr. Shan announced "another clinical study of COLD-fX has met rigorous scientific scrutiny and has been accepted by a peer-reviewed journal for publication." The study is published in the Journal of Alternative and Complementary Medicine. "It is apparent from this study that COLD-fX treatment was effective in reducing the incidence and duration of ARI- [acute respiratory illness] related symptoms in healthy community-dwelling adults aged 65 years and older," it said. Curiously, given such a strong endorsement and the company's practice of using trial results to promote its product, CV Technologies has not reported any of the results in its news releases or advertisements. Mr. Baines also asked several questions about the researchers' methodology and what the researchers specifically intended to measure. He also asked why the study, which was conducted in 1998, is just now being published. In all cases, company officials did not respond.

[Onthego]

VAS-T NR today 84m at 2.38

Vasogen to release Q1 results April 17; call


2006-04-11 11:12 ET - News Release

Mr. Glenn Neumann reports

VASOGEN TO CONDUCT QUARTERLY CONFERENCE CALL

Vasogen Inc. will release its quarterly results after the close of the North American financial markets on Monday, April 17, 2006. A live webcast presentation and conference call will be conducted on Tuesday, April 18, 2006, at 8:30 a.m. ET, during which management will provide a company update and discuss first quarter results.

To participate via live webcast and view the slide presentation, please go to the company's website.

To participate by telephone, please connect 10 minutes prior to the call to one of the following:


Direct dial: 416-695-6622

Toll-free: 1-800-769-8320


Telephone participants can also log onto the company's website to follow the slide presentation and will have the opportunity to ask questions.

A rebroadcast of the conference call will be available at the company website and may also be accessed by:


Direct dial: 416-641-2126

Toll-free: 1-800-293-5765, pin code: 8019


We seek Safe Harbor.

[Onthego]

ONC-T NR today 36m at 5.00

Oncolytics receives patent No. 2,415,750


2006-04-11 05:23 ET - News Release

Ms. Cathy Ward reports

ONCOLYTICS BIOTECH INC. ANNOUNCES ISSUANCE OF 5TH CANADIAN PATENT

Oncolytics Biotech Inc. has been granted Canadian patent 2,415,750, entitled, "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders." The claims describe methods for preventing reovirus recognition by the host immune system, while concurrently or subsequently administering reovirus, resulting in substantial lysis of the proliferating cells.

"The claims in this Canadian patent allow manipulation of the immune system that may enhance the effectiveness of Reolysin treatment," said Dr. Matt Coffey, chief scientific officer of Oncolytics. "Oncolytics has secured patent protection for this new treatment modality in the United States, and we are pleased to add this protection to our Canadian patent portfolio."

We seek Safe Harbor.

[Onthego]

MPH-T NR today 79m at 1.94

Medicure to present Matched study results at ASH 2006


2006-04-10 10:06 ET - News Release

Mr. Derek Reimer reports

MEDICURE TO PRESENT MATCHED RESULTS AT THE 21ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF HYPERTENSION

Medicure Inc.'s two posters outlining the positive results of the phase II Matched study with MC-4232 have been accepted for presentation at the American Society of Hypertension (ASH) annual scientific meeting and exposition being held in New York at the New York Hilton Hotel from May 16, 2006, to May 20, 2006. ASH is the largest U.S. organization dedicated exclusively to hypertension and related cardiovascular disease.

"We look forward to presenting the Matched clinical results at this important scientific forum," stated Dr. Lacourciere, MD, FRCP, FACP, principal investigator of the Matched study. "The opportunity to present the results validates the importance of the study's findings and the expanding need for new approaches to treat patients with diabetes and hypertension."

"This is an ideal setting for our first formal presentation of the Matched clinical results," commented Medicure's president and chief executive officer, Albert D. Friesen, PhD. "Patients with co-existing diabetes and hypertension, like those studied in Matched, are extremely difficult to treat and frequently require multiple drugs to control their cardiovascular and metabolic risk factors. MC-4232, as demonstrated in Matched, is currently one of the only drugs in development that addresses both cardiovascular and metabolic risk factors in this difficult to treat patient population."

Dr. Lacourciere, director of the hypertension research unit, Centre Hospitalier de l'Universite Laval Sainte-Foy in Quebec, will present the two posters describing the anti-hypertensive and metabolic effects of MC-4232. The abstract, which is titled evaluation of the anti-hypertensive effects of MC-1 alone and in combination with lisinopril on ambulatory BP in hypertensive patients with Type 2 diabetes mellitus, will be presented at 8:30 a.m. Eastern Time on May 17, 2006. The second abstract, which is titled the combination of MC-1 and lisinopril has beneficial effects on carbohydrate and lipid metabolism in hypertensives with Type 2 diabetes mellitus, will be presented at 4 p.m. Eastern Time on May 16, 2006.

Medicure completed the phase II Matched study (MC-1 and ACE therapeutic combination for hypertensive diabetics) in September, 2005. The study results demonstrated that MC-4232 had a statistically significant reduction in both primary blood pressure and metabolic end points.

We seek Safe Harbor.

[Onthego]

GNBT NR today 2.88

Generex Biotechnology Announces Results of a Trial Using Generex Oral-lyn(TM) in Adolescent and Young Adult Patients With Type-1 Diabetes Mellitus


2006-04-10 09:00 ET - News Release

TORONTO -- (MARKET WIRE) -- 04/10/06

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=122201&ProfileId=051205&am...
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery and developer of Generex Oral-lyn™, the Company's proprietary oral insulin spray product, announced today interim three-month results of a long-term six-month clinical trial performed in 24 adolescents and 5 young adult patients with Type-1 diabetes mellitus (DM). This data continuously showed that replacing just 1 one daily subcutaneous injection (s.c.) of regular insulin with Generex Oral-lyn™ during the day, improves parameters of metabolic control in the same manner observed with intensively monitored standard therapy.

At the 3rd month evaluation of this six-month trial, it was demonstrated that a trend similar towards normalization exists when replacing the lunch-time dose of regular insulin with the Generex Oral-lyn™ spray. In fact, not only Daily Glucose Profiles and Fructosamine demonstrated improved values but, of special importance, Glycosylated Hemoglobin (HbA1c), the criterion standard to evaluate metabolic control in Diabetes, showed a significant improvement when compared to standard therapy. The investigators concluded, in their three-month interim analysis, that successful and efficient replacement of injected regular insulin at lunchtime was achieved with Generex Oral-lyn™ altogether with 100% compliance.

These encouraging results prompted the investigators and the partners Generex-Pharmabrand to design studies using larger number of Type-1 DM subjects and replacing the three mealtime doses of regular insulin with the Generex-Oral-lyn™ spray on subjects maintained in once daily glargine insulin therapy. These larger studies will be designed for approval in Canada and other countries.

Marketing Program sponsored by the Consortium Generex-Pharmabrand.-

The above mentioned data was presented and discussed in a seminar that included a marketing program. It was held by the Company's Joint Venture partner, PharmaBrand SA. All three-month results in safety and efficacy were discussed in Quito, Ecuador by Dr. Jaime Guevara-Aguirre M.D. during a meeting of 150 doctors (Pharmabrand sponsored this meeting as part of its post-approval marketing program). The results were received with enthusiasm by the doctors who will make use of them when Generex Oral-lyn™ is marketed and distributed nationwide in the next few weeks.

A week-long training seminar concluded Thursday, April 6, 2006, for the PharmaBrand S.A. sales force, which is preparing to begin nationwide marketing of the first commercial run of Generex Oral-lyn™ produced in Ecuador.

The April 2006 issue of Pediatrics features a study on the prevalence and correlation of depressed mood in adolescents with diabetes, entitled, "Prevalence and Correlates of Depressed Mood Among Youth with Diabetes." The results of the study showed an association between higher mean HbA1c and frequency in emergency room visits, and depressed mood. "The Pediatrics study demonstrates the vicious cycle created by a breakdown of therapy, increased complications leading to depressed moods in adolescents. Dr. Guevara-Aguirre's results shows that patient friendly Generex Oral-lyn™ leads to continuous compliance in adolescents," said Anna Gluskin, Generex's President & Chief Executive Officer.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: [phone]
and [phone]

Ed Lewis
CEOcast, Inc.
Phone: [phone]

[Onthego]

HEB NR 04/05/06 3.31

HBSC and HEB Update the Investment Community in All-New Interviews With www.wallst.net


2006-04-05 07:00 ET - News Release

Also News Release (U-HBSC) HUMAN BIOSYSTEMS



NEW YORK, April 5 /PRNewswire/ -- On March 31, Harry Masuda, CEO of Human BioSystems, Inc. updated the investment community in an all-new interview with www.wallst.net . Interview highlights include detailed discussions on the following topics:

-- how the company's blood platelet and organ preservation technology
improves on current standards
-- how the company's technology could reduce healthcare costs
for patients
-- recently closed $3.3 million financing
-- trends in the market bolstering the company's prospects for growth
-- lack of competition
-- upcoming milestones for investors to watch for

To hear the interview in its entirety, and to read an in-depth report on the company, visit http://wallst.net/superstock/hbsc/hbsc.html

On March 24, Dr. William Carter, Chairman and CEO of Hemispherx Biopharma, Inc. updated the investment community in an all-new interview with www.wallst.net . Interview highlights include detailed discussions on the following topics:

-- reasons why the company's patented drug, Ampligen, is considered a
strong candidate for treating avian flu
-- "broad economic implications" of recent test results
-- when the company expects to see earnings from its influenza drugs
-- trends in the company's target markets, and why the company is
positioned to capitalize on these trends
-- competitive edge
-- intellectual property

To hear the interviews in their entirety, visit http://www.wallst.net , and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" page or by entering the respective company's ticker symbol in the Search Archive window at the bottom of the "Interviews" page.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO )

About WallSt.net

www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive two thousand two hundred fifty dollars from Human BioSystems, Inc. for media and advertising services. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp .

Contact:
Nick Iyer
Digital Wall Street, Inc.
1-800-4-WALL-ST

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [e-mail]
WallStreet Direct, Inc.



CONTACT: Nick Iyer of Digital Wall Street, Inc., 1-800-4-WALL-ST



Web site: http://wallst.net/superstock/hbsc/hbsc.html/
http://www.wallst.net/disclaimer/disclaimer.asp/
http://www.wallst.net/

[Onthego]

AEMD NR 04/05/2006 at .78

Aethlon Medical CEO Named to Biodefense Panel at the 2006 Homeland and Global Security Summit


2006-04-05 09:00 ET - News Release

SAN DIEGO -- (Business Wire) -- April 5, 2006
Company Website: http://www.aethlonmedical.com

Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in
developing therapeutic devices for infectious disease, announced today
that its Chairman and CEO, James A. Joyce has been named to the
Biodefense Priorities, Programs, and Funding Panel at the 2006
Homeland and Global Security Summit. The Summit is being held on April
11 at the Washington Convention Center in Washington, D.C. The other
panel members are:

-- Steven Perkins, Vice President, Business Development and
Strategy, Northrop Grumman Corporation.

-- Dr. Charles R. Gallaway, Director, Chemical-Biological Defense
Directorate, Defense Threat Regulatory Agency (DTRA).

-- Major General Bruce E. Davis, Commander, Joint Task Force
Civil Support, US Northern Command.

Additional details on the 2006 Homeland and Global Security Summit
can be accessed at
www.globalsecurity.bz/conferences/current_conferences/hgss/2006/index.
asp.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat
infectious disease. The device, known as the Hemopurifier(TM), is a
broad-spectrum treatment countermeasure against drug and vaccine
resistant bioweapons, naturally evolving pandemic threats such as H5N1
Avian Flu, and chronic infectious disease targets including
Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon
has also initiated research on a second generation Hemopurifier(TM)
that targets the capture of growth factors inherent in the spread of
Cancer. More information on Aethlon Medical and the Hemopurifier(TM)
technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.
Contacts:

Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800 ext. 302
[e-mail]
or
James A. Joyce, 858-459-7800 ext. 301
[e-mail]

[Onthego]

LOR-T NR today 173m at .37

Lorus Therapeutics cuts Q3 loss to $4.09-million


2006-04-07 08:16 ET - News Release

Ms. Grace Tse reports

LORUS THERAPEUTICS REPORTS THIRD QUARTER RESULTS FOR FISCAL YEAR 2006

Lorus Therapeutics Inc. has released its financial results for the three- and nine-month periods ended Feb. 28, 2006.

Dec. 1, 2005, to date, highlights:


In early December, Lorus announced positive findings in its clinical trial of GTI-2040 combined with cytarabine in patients with recurrent or refractory acute myeloid leukemia (AML) sponsored by the National Cancer Institute (NCI). These patients have few remaining treatment options and without novel therapies are candidates for bone marrow transplants. The clinical trial data presented showed complete responses in 44 per cent of patients 60 years of age or younger. Patients in this trial had either failed to respond to prior therapy or had rapidly relapsed. Such patients usually have a very low expectation of complete response of approximately 10 to 20 per cent on salvage therapies such as high-dose cytarabine.
Although clinical results from the phase III trial of Virulizin for the treatment of pancreatic cancer did not reach statistical significance in overall mean survival times, Lorus recently announced the observations of further exploratory analysis of the data from this trial. This analysis showed survival benefit for a subgroup of patients who continued to receive Virulizin after entering optional stage 3 second-line therapy. Stage 3 patients are those who entered optional second-line therapy, and were offered Virulizin/placebo plus 5-flurouracil, or Virulizin/Placebo alone or best supportive care.
Lorus announced publication of three research studies for its anti-cancer products, providing support for further development of Lorus's lead small molecule program and two anti-sense drugs. The publications discussed the following topics:
Novel formulation developed for ML-series of small molecule compounds;
GTI-2501 preclinical data indicate a broad spectrum of anti-tumour activity; and
GTI-2601 exhibits anti-tumour effects.

"We have continued to focus our activities during the quarter on partnerships for our two most advanced drug candidates, GTI-2040 and Virulizi, while progressing the development of our small molecule program and the GTI-2040 phase II clinical trial program supported by the U.S. NCI," said Dr. Jim Wright, president and chief executive officer. "We are encouraged with the results during the quarter from our AML NCI sponsored GTI-2040 phase II clinical trial and we look forward to more data from the remaining five NCI sponsored clinical trials throughout the calendar year."

Financial results

Cash used in operating activities before changes in non-cash working capital was $2.7-million for the three-month period ended Feb. 28, 2006, compared with $4.1-million in the prior period. For the nine-month period ended Feb. 28, 2006, cash used in operating activities before changes in non-cash working capital totalled $11.0-million, compared with $14.2-million in the prior period. The decrease during the quarter is primarily due to lower research and development expenditures due to the close of the Virulizin phase III clinical trial in July, 2005, as well as lower general and administrative costs resulting from lower levels of staff following the November, 2005, corporate changes and reduced legal, patent and consulting costs.

Net loss for the three months ended Feb. 28, 2006, totalled $4.1-million (two cents per share), compared with a loss of $5.3-million (three cents per share) for the same period last year. For the nine-month period ended Feb. 28, 2006, net loss totalled $14.9-million (nine cents per share) compared with $17.5-million (10 cents per share) for the comparable period last year. The year-to-date decrease in net loss is due primarily to a reduction of $3.2-million in research and development expenses, and a reduction of $200,000 in general and administrative expenses offset by higher interest expense of $496,000 and accretion expense of $373,000 associated with the debentures issued in fiscal 2005.

Research and development expenses for the three-month period ended Feb. 28, 2006, decreased to $2.3-million compared with $3.2-million for the same period last year. For the nine-month period ended Feb. 28, 2006, research and development expenses decreased to $8.9-million, compared with $12.1-million for the same period last year. The decrease in research and development activities is the result of lower clinical trial costs for the now complete phase III trial of Virulizin in comparison with the prior year when the trial was fully enrolled and under way. In addition, due to the corporate changes in November, 2005, the number of personnel working on Virulizin research and development activities has decreased.

General and administrative expenses for the three-month period ended Feb. 28, 2006, decreased 39 per cent to $909,000, compared with $1.5-million in the same period last year. General and administrative expenses for the nine-month period ended Feb. 28, 2006, decreased slightly to $3.6-million, compared with $3.8-million in the same period last year. The decrease in general and administrative costs during the quarter is the result of lower levels of staff following the November, 2005, corporate changes as well as lower legal, patent and consulting costs compared with the prior year. The reduction year to date is less significant due to severance costs of $468,000 resulting from corporate changes in November, 2005.

Interest income for the three months ended Feb. 28, 2006, was $85,000, compared with $116,000 for the same period last year. For the nine months ended Feb. 28, 2006, interest income was $295,000, compared with $397,000 for the same period last year. The decrease is attributable to a lower cash and short-term investment balance throughout fiscal 2006.

At Feb. 28, 2006, Lorus had cash and cash equivalents and short-term investments totalling $10.3-million compared with $21.5-million at May 31, 2005. Working capital was $7.4-million at Feb. 28, 2006, compared with $18.5-million at May 31, 2005.


CONSOLIDATED STATEMENT OF
LOSS AND DEFICIT
Three months ended Feb. 28
(thousands of dollars)

2006 2005

Revenue $ 5 $ 3
--------- ---------
5 3
--------- ---------
Expenses

Cost of sales 1 -

Research and
development 2,296 3,175

General and
administrative 909 1,484

Stock-based
compensation 400 341

Depreciation
and amortization 130 128
--------- ---------
Operating
expenses 3,736 5,128

Interest expense
on convertible
debentures 224 96

Accretion in
carrying
value of
convertible
debentures 202 137

Amortization
of deferred
financing
charges 23 32

Interest
income (85) (116)
--------- ---------
Loss for
the period 4,095 5,274
========= =========
Basic and
diluted
loss per
common
share $ 0.02 $ 0.03
========= =========

CONSOLIDATED STATEMENT OF
LOSS AND DEFICIT
Nine months ended Feb. 28
(thousands of dollars)

2006 2005

Revenue $ 12 $ 6
--------- ---------
12 6
--------- ---------
Expenses

Cost of sales 2 1

Research and
development 8,884 12,062

General and
administrative 3,604 3,842

Stock-based
compensation 1,105 1,202

Depreciation
and amortization 390 379
--------- ---------
Operating
expenses 13,985 17,486

Interest expense
on convertible
debentures 631 135

Accretion in
carrying
value of
convertible
debentures 568 195

Amortization
of deferred
financing
charges 62 51

Interest
income (295) (397)
--------- ---------
Loss for
the period 14,939 17,464
========= =========
Basic and
diluted
loss per
common
share $ 0.09 $ 0.10
========= =========

We seek Safe Harbor.

[Onthego]

MPH-T NR today 79m at 1.95

Medicure gets positive results in MEND-CABG phase II


2006-04-06 09:21 ET - News Release

Mr. Derek Reimer reports

MEDICURE REPORTS POSITIVE POD 90 RESULTS FROM THE MEND-CABG STUDY -- MC-1 TREATMENT EFFECT MAINTAINED AT 90 DAYS POST OPERATIVELY

Medicure Inc. has received positive postoperative day (POD) 90 results with its lead cardioprotective product, MC-1, from the phase II MEND-CABG study. The MEND-CABG study was a double-blind, parallel-group, randomized, placebo-controlled study in 902 patients who underwent coronary artery bypass graft (CABG) surgery.

The primary end point of MEND-CABG was the reduction in the composite of cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke up to POD 30. Positive POD 30 results were reported in Stockwatch on Dec. 5, 2005. In addition to the POD 30 analysis, the study protocol included following study patients for 90 days postoperatively (POD 90) for further safety and efficacy analysis.

MEND-CABG study results

The MEND-CABG POD 90 results further demonstrated the positive clinical effects of MC-1:


the clinical results reported at POD 30 with MC-1, as noted below, were maintained throughout the follow-up period; and
the safety analysis demonstrated MC-1 was safe and well tolerated. The incidence of adverse events in the study was comparable across both treatment and control groups.

The MEND-CABG POD 30 results released in December, 2005, demonstrated the positive clinical effects of MC-1:


the 250-milligram dose of MC-1 had a 37.2-per-cent reduction in the composite of cardiovascular death, non-fatal myocardial infarction (peak CK-MB greater than or equal to 100 ng per millilitre), and non-fatal stroke compared with placebo (p equals 0.028);
the reduction in the composite end point was driven by a substantial decrease in the incidence of non-fatal myocardial infarction, most notably a 46.9-per-cent reduction in non-fatal myocardial infarction (peak CK-MB greater than or equal to 100 ng per millilitre) with the 250 milligrams of MC-1 compared with placebo (p equals 0.008); and
the 250-milligram dose of MC-1 had a 14-per-cent reduction in the primary end point composite of cardiovascular death, non-fatal myocardial infarction (peak CK-MB greater than or equal to 50 ng per millilitre), and non-fatal stroke compared with placebo (p equals 0.312).

Medicure plans to present the detailed results from MEND-CABG, including the POD 90 analysis, at an upcoming scientific conference.

"The maintenance of the clinical reductions at POD 90 further supports MC-1's ability to significantly reduce heart attacks in this high-risk patient population and clearly warrant advancing MC-1 into pivotal phase III development," commented Medicure's president and chief executive officer, Dr. Albert Friesen, PhD. "These results suggest that MC-1 could represent a major therapeutic breakthrough in the treatment of acute ischemia and ischemic reperfusion injury. We will meet with the FDA to discuss these results and develop the phase III program, which we anticipate commencing in the second half of 2006."

MEND-CABG study

The MEND-CABG trial was designed to evaluate the cardioprotective and neuroprotective effects of MC-1 in high-risk coronary artery disease patients undergoing CABG surgery. The trial enrolled 902 patients at 42 investigational sites throughout Canada and the United States. The study was a double-blind, parallel-group, randomized, placebo-controlled study in patients who underwent coronary artery bypass graft surgery. Study patients received placebo or MC-1 (250 milligrams or 750 milligrams) on the day of surgery and for 30 days postoperatively (POD 30). The primary end point of MEND-CABG was a reduction in the composite of cardiovascular death, non-fatal myocardial infarction (heart attacks), and non-fatal stroke up to POD 30. Study patients were followed for 60 days after treatment (90 days postoperatively) for additional safety and efficacy analysis.

MC-1

MC-1 is a naturally occurring small molecule that reduces the amount of damage to the heart following ischemia or ischemic reperfusion injury. Studies with MC-1 suggest that it does this by protecting cardiomyocytes (heart muscle cells). Since cardiomyocytes are essential for normal heart function and do not regenerate themselves following an ischemic event, their preservation is key to minimizing ischemic damage and maintaining proper heart function. MC-1's cardioprotective properties have now been demonstrated in the phase II MEND-1 study in patients undergoing percutaneous coronary interventions and the phase II MEND-CABG study in patients undergoing CABG surgery.

We seek Safe Harbor.

[Onthego]

SSB-T NR today 83m at .65

Stressgen names Rieder to board; Lennox resigns


2006-04-06 08:27 ET - News Release

Ms. Donna Slade reports

Stressgen Biotechnologies Corp. is appointing Robert Rieder, vice-chairman and chief executive officer of Cardiome Pharma Corp., to the board of directors. In addition, Dr. Jay Short, PhD, has been appointed chairman of the board, replacing R. Ian Lennox who is resigning from the board.

"We are extremely pleased with Bob Rieder's appointment to our board of directors," commented Gregory McKee, president and chief executive officer. "We believe his extensive experience in the health care industry and exemplary track record building Cardiome Pharma make him an ideal addition to our board. We are also pleased that Jay Short has agreed to serve as chairman, providing continued scientific and business leadership. We would like to take this opportunity to sincerely thank Ian Lennox for his dedicated service and significant contribution to the company."

Mr. Rieder joined Cardiome in April of 1988 as president and chief executive officer, and was recently appointed as the company's vice-chairman of the board. Mr. Rieder has extensive experience in venture capital and in operational management. Prior to joining Cardiome, he was vice-president at MDS Ventures Pacific Inc., the Vancouver-based affiliate of MDS Capital Corp., and has served as a director for nine public and private technology companies. In his venture capital career, Mr. Rieder led several rounds of financing for Stressgen and was a director of the company from 1992 until 2000. Prior to joining MDS, Mr. Rieder was president and chief executive officer of Synapse Technologies and chief operating officer of DBA Telecom Inc. Mr. Rieder received his BASc (chemical engineering) from the University of British Columbia and his MBA from the University of Western Ontario.

Dr. Short has served on the Stressgen board of directors for 12 years. In 2005, Dr. Short became chairman, president and founder of the E.O. Wilson Biodiversity Foundation in San Diego, Calif. Dr. Short served as president, chief executive officer, chief technology officer, director and founder of Diversa Corp. from September, 1994, to October, 2005.

[Onthego]

QLT-T NR today 91m at 8.79

Post says QLT, others look across border for help


2006-04-06 07:42 ET - In the News

The Financial Post reports in its Thursday edition almost half of Canada's biotech companies are planning to move all or part of their business outside Canada to more business-friendly areas. CanWest's Gillian Shaw writes that is according to a joint report from BIOTECanada and PricewaterhouseCoopers. The responses from the cross-Canada survey indicate the country stands to lose almost half of its life science and biotech companies if it fails to provide a more sustainable business environment. "When we see 48 per cent of companies are looking to move all or part of their companies outside Canada, it raises an alarm," said Peter Brenders, president of BIOTECanada. "I think we can do better and I think this is a wakeup call." A range of factors are to blame. There are tax considerations that deters foreign investment in Canadian companies. Also, immigration policies make it difficult for companies here to attract much-needed talent. And there is a lack of venture capital, particularly for early-stage biotechs. The report was released on the same day as QLT announced it is partnering with a Seattle company to develop new drugs for the prevention and treatment of degenerative diseases of the retina.

[Onthego]

QLT.T NR yesterday 91m at 8.79

QLT wins stay of Eligard injunction, pending appeal


2006-04-05 22:30 ET - News Release

Ms. Therese Hayes reports

QLT ANNOUNCES THAT COURT OF APPEALS GRANTS STAY OF INJUNCTION AGAINST ELIGARD(R) SALES

The U.S. Court of Appeals for the Federal Circuit has entered a decision to stay the injunction against the manufacture and sale of QLT USA Inc.'s Eligard products that was entered on Feb. 27, 2006, by the U.S. District Court for the Northern District of Illinois, eastern division.

Previously, the Court of Appeals had temporarily stayed the injunction while it was considering the motion for a stay filed by QLT USA and co-defendant Sanofi-Synthelabo Inc. Following the earlier injunction decision, QLT USA's U.S. marketing partner for Eligard, Sanofi-Synthelabo, had previously announced that it was discontinuing sales of Eligard in the U.S. until the expiry of the patent on May 1, 2006, that is the subject of the litigation with TAP Pharmaceuticals Products Inc. As a result of the decision and reasons of the Court of Appeals to grant a stay of the injunction, Sanofi-Synthelabo has advised QLT USA it will relaunch Eligard in a limited manner in order to serve the public interest of patient safety.

Under the order issued by the Court of Appeals, QLT USA is required to deposit into escrow the net Eligard sales revenues from the date of the injunction, Feb. 27, 2006, until the expiration of the patent on May 1.

QLT USA's appeal of the District Court's judgment on liability in favour of TAP Pharmaceutical Products Inc. and co-plaintiffs continues.

We seek Safe Harbor.

[Onthego]

Sorry, I am not familar with that one - 3 mo. daily chart show some support though.

[Sultan]

Any opinion on COM.TO

[Onthego]

QLT-T NR today 91m at 8.77

QLT partners in ocular synthetic retinoid program


2006-04-05 05:40 ET - News Release

Ms. Therese Hayes reports

QLT ANNOUNCES CO-DEVELOPMENT AND LICENSING AGREEMENT WITH RETINAGENIX FOR EARLY STAGE OCULAR SYNTHETIC RETINOID PROGRAM

QLT Inc. has entered into an exclusive worldwide co-development and licensing agreement with Retinagenix LLC to develop active synthetic retinoid products for the treatment of degenerative retinal diseases.

Under the terms of the agreement, QLT will be responsible to develop and commercialize the products for use in ocular and all other human diseases. Retinagenix will participate in research in support of the co-development collaboration, and be eligible to receive an upfront payment of $1.5-million (U.S.), and payments upon achievement of certain development, approval and sales milestones, as well as a single-digit royalty on net sales.

"We are very excited to make this announcement today," said Bob Butchofsky, president and chief executive officer of QLT. "This collaboration is the first step forward in our strategy to access, develop and commercialize promising new technologies in the eye, which is QLT's core area of therapeutic expertise. We plan to progress the first drug candidate from the Retinagenix collaboration into the clinic within the next 18 months."

"Degenerative diseases of the retina affect many people worldwide and lead to varying degrees of irreversible blindness," said Marco Northland, chairman of Retinagenix. "We believe that administration of a synthetic retinoid could reverse the defects in the retinoid cycle in patients. We believe QLT's expertise in retinal diseases and drug development, provide a strong foundation for a successful collaboration."

We seek Safe Harbor.

[Onthego]

CJC NR today 47m at 1.45

Globe says ConjuChem learns trick to raising cash


2006-04-05 07:57 ET - In the News

The Globe and Mail reports in its Wednesday, April 5, edition that biotechnology companies like ConjuChem are strapped for cash. The Globe's Leonard Zehr writes there are more firms with less cash in the industry. ConjuChem needs money to complete important clinical trials for its diabetes drug. Yet the shares have been drifting at $1.50 for about six months and any further dilution would be undesirable. ConjuChem shares traded at $14 two years ago before a different clinical test produced unsatisfying results. Fortunately for the company, chief financial officer Lennie Ryer had an idea. The company sold its tax-loss credits in February for $6.4-million. These assets would otherwise have simply expired unused. Mr. Ryer commented, "Basically we turned a worthless asset into $6.4-million without issuing a single share, which is a pretty neat trick." The trick will help ConjuChem test its diabetes drug, and this may lead to a marketing deal later this year. Yet the trend of cash-strapped biotechnology companies continues. Market capitalization in the sector fell by almost $500-million (U.S.) in 2005. Ernst & Young thinks there will be more consolidation as junior companies find it hard to raise cash.

[Onthego]

GNBT NR 04/03/06 2.705

Quality Stocks: Bird Flu Penny Stock Picks Gain up to 325 Percent


2006-04-03 07:00 ET - News Release

Also News Release (U-EFSF) EFOODSAFETY.COM INC
Also News Release (U-STTK) SMART-TEK SOLUTIONS INC
Also News Release (U-VICL) VICAL INC


SCOTTSDALE, Ariz., April 3, 2006 (PRIMEZONE) -- Quality Stocks: Bird flu stocks saw repeated coverage from online penny stock investment newsletters in March 2006 and gained as much as 325% for the month.

The biggest percentage gain was Smart-tek Solutions Inc. (OTCBB:STTK), beginning the month at $0.24 and closing on March 31 at $1.02, for a 325% gain. The stock achieved double digit positive gains for the day on multiple trading days in the month. On March 30 the company announced that it is in advanced stages to introduce its RTAC-PM poultry monitoring and containment system to officials in Singapore. Additional investor coverage was provided by investment newsletters Hot OTC, Hot Stock Chat, Stock Egg and OTC Stock Exchange.

Generex Biotechnology Corporation (Nasdaq:GNBT) opened the month at $2.29 and had almost doubled by March 21 when it closed at $4.23. The stock has since retraced some of those gains to close the month up 39% at $3.07. Additional investor coverage throughout March was provided by investment newsletters CEOCast, Shazam Stocks, Stock Egg and Hot OTC.

eFoodSafety.com, Inc. (OTCBB:EFSF) saws a 55% gain in its share price on March 27 following news that its Citroxin formulation has proven in independent laboratory testing to eliminate the H9N2 virus. Additional investor coverage on March 27 was provided by Small Cap Voice, with other investor coverage throughout March by Investor Spec Sheet, Stock Egg, OTC Picks and OTC Stock Exchange.

Shares of Vical Inc. (Nasdaq:VICL) jumped almost 15% on Friday after the biotech company announced that mice which were given its flu vaccine were protected against lethal levels of flu virus from two strains. The stock closed at $ 6.18 on March 31 compared to an opening price of $ 4.75 on March 1 for a 30% gain on the month. Vical Inc. was covered by The Subway investment newsletter on March 31.

About Quality Stocks

Quality Stocks is a free service that collates the Micro Cap Stock Picks featured by more than 150 online Investment Newsletters into one free Daily Newsletter Report.

To sign up for the free Quality Stocks Daily Newsletter Report, visit www.qualitystocks.net.

Quality Stocks Disclaimer

Quality Stocks receives no compensation for any of the stocks mentioned in the Quality Stocks Daily Newsletter Report or in our Press Releases. We just report on what is happening out there.

CONTACT: Quality Stocks
Mike Brown, Editor
[e-mail]

[Onthego]

HEB NR 04/03/06 3.19

Hemispherx Biopharma, Inc. Announces Delay in Filing Its Form 10-K for the Fiscal Year Ended December 31, 2005


2006-04-03 09:27 ET - News Release

PHILADELPHIA -- (Business Wire) -- April 3, 2006
Company Website: http://www.hemispherx.net

Hemispherx Biopharma, Inc. (AMEX:HEB) (the "Company")
announced today that it would not be filing its annual report on Form
10-K for the fiscal year ended December 31, 2005, on March 31, 2006,
the extended due date.
During the preparation of the Company's annual report on Form 10-K
for the fiscal year ended December 31, 2005, after discussions with
the audit committee and BDO Seidman, LLP, the Company's Independent
Registered Public Accounting Firm, and after doing additional analysis
on guidelines set forth in EITF 00-27: Application of Issue No. 98-5
to Certain Convertible Instruments, it was determined that an
incorrect accounting principle was applied to certain Debentures and
Warrants issued between March 2003 and August 2005, which impacted the
Company's financial statements between March 2003 and September 2005,
specifically, the initial recording of the embedded conversion feature
of the Debentures and the related fair value of related warrants as
well as certain Debenture and Warrant price resets.
All of the above issues relate to accounting for convertible debt,
additional paid-in capital and related non-cash financing charges.
These non-cash charges do not affect the Company's revenues, cash
flows from past or future operations, or its liquidity.
After discussions with the audit committee and BDO Seidman, LLP,
the Company's Independent Registered Public Accounting Firm, the Audit
Committee agreed with management's recommendations and concluded that
the previously issued financial statements included in the Forms 10-Q
and Forms 10-K for the periods ended from March 31, 2003 to December
31, 2005, should not be relied upon.
The Company has filed its Form 10-K for the year ended December
31, 2005 (the "Report") without audited financial statements. The
anticipated restatements of the Company's financial statements for the
years ended December 31, 2003 and 2004 are contained therein. As
audited financial statements are not contained in the Report, the
Report does not satisfy all requirements under the Securities Exchange
Act and, therefore, is deficient. Based on representations from BDO
Seidman, LLP, the Company anticipates that it will file an amendment
to the Report containing audited financial statements within the next
30 days, and file its Forms 10-Q for the quarters ended March 31, 2005
and 2004, June 30, 2005 and 2004, and September 30, 2005 and 2004 as
soon as practicable thereafter.

About Hemispherx Biopharma

Hemispherx Biopharma, based in Philadelphia, is a
biopharmaceutical company engaged in the manufacture and clinical
development of new drug entities for treatment of viral and
immune-based chronic disorders. Hemispherx Biopharma's flagship
products include Alferon(R) and the experimental
immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). Alferon(R)
is approved for a category of STD infection, and Ampligen(R) and
Oragens(TM) represent experimental nucleic acids being developed for
globally important viral diseases and disorders of the immune system.
Hemispherx's platform technology includes large and small agent
components for potential treatment of various chronic viral
infections. Hemispherx has in excess of 140 patents comprising its
core intellectual property estate, a fully commercialized product
(Alferon(R) N) and GMP certified manufacturing facilities for its
novel pharma products. For more information please visit
www.hemispherx.net

Information contained in this news release other than historical
information, should be considered forward-looking and is subject to
various risk factors and uncertainties. For instance, the strategies
and operations of Hemispherx involve risk of competition, changing
market conditions, change in laws and regulations affecting these
industries and numerous other factors discussed in this release and in
the Company's filings with the Securities and Exchange Commission. Any
specifically referenced investigational drugs and associated
technologies of the company (including Ampligen(R), Alferon(R) LDO and
Oragens) are experimental in nature and as such are not designated
safe and effective by a regulatory authority for general use and are
legally available only through clinical trials with the referenced
disorders. The forward-looking statements represent the Company's
judgment as of the date of this release. The Company disclaims,
however, any intent or obligation to update these forward-looking
statements. Clinical trials for other potential indications of the
approved biologic Alferon(R) do not imply that the product will ever
be specifically approved commercially for these other treatment
indications.
Contacts:

Hemispherx Biopharma, Inc.
Company Contact:
Dianne Will, 518-398-6222
[e-mail]
or
Media Contact:
Neale-May & Partners
Digs Majumder, 212-213-5400 x 206
[e-mail]

[Onthego]

AEMD NR today .84

Global Demand Supports Development of Avian Flu Treatments and Antiviral Drugs


2006-04-03 09:00 ET - News Release

Also News Release (U-BGTH) BRIDGETECH HLDGS INTL INC
Also News Release (U-GNBT) GENEREX BIOTECH CP
Also News Release (U-HEB) HEMISPHERX BIOPHARMA INC


POINT ROBERTS, WA and DELTA, BC -- (MARKET WIRE) -- 04/03/06

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=115855&ProfileId=051205&sourceType=1" target="_blank">http://media.marketwire.com/attachments/200406/183384_CAS.gifhttp://at.marketwire.com/accesstracking...
www.China-AsiaStocks.com (CAS) and www.BiotechIndustryStocks.com (BIS) , investor and industry news portals for the China-Asia and biotechnology sectors, feature "Global Demand Boosts Avian Flu Vaccine Market," for investors and industry following developments in the vaccine market. Biotech and Healthcare companies: Bridgetech Holdings International Inc., Generex Biotech, AVI Biopharma Inc., Hemispherx Biopharma, Inc, Carrington Laboratories and Aethlon Medical discuss unique approaches to this potential global dilemma and offer insight to possible solutions.

Dr. Carlton Turner, President and CEO of Carrington Laboratories, gave an overview on the market, commenting that, "Policymakers from around the world are responding as best they can to the threat of an H5 Avian Flu pandemic. The challenge lies in trying to find the right antigen, producing enough of it to protect the world's population and then finding a way to deliver it to large populations efficiently."

Michael Chermak, CEO for Bridgetech Holdings International Inc (OTC: BGTH), has provided insights with respect to the effect the Avian Flu has had on China's healthcare market, "The impact of the Avian Flu outbreak on the Chinese healthcare system has been profound. The resulting self examination has created a sense of urgency, regarding the modernization and improvement of the entire system."

Vice President of Generex (NASDAQ: GNBT) and President of Antigen Express, Dr. Eric Vonhofe, expressed great confidence in their product, explaining that," Last fall, the government paid about $100 million for an egg-based vaccine, but that will probably be enough for only about 3 million people. In contrast, our vaccine which is synthetic can be made on a 100 kg scale quickly, efficiently and at a relatively inexpensive rate."

AVI Biopharma Inc., a producer of antiviral drugs, has established avian influenza H5N1 as a priority within the company. Michael Hubbard, Director of Investor Relations for the company, said that, "We are moving as quickly as we can on Avian Flu, given the urgency. As soon as we have the safety data, we can apply for a new drug application with the FDA, which we hope to do before year's end." Dr. David Strayer, Medical Director at Hemispherx Biopharma, Inc. (AMEX: HEB), also pointed out that, "This area could move very rapidly because there is an urgent need for a better way to treat and prevent Avian influenza. I think there is great potential here for our company."

However, antiviral drugs currently being stockpiled as part of a global strategy to treat Avian Flu may have little therapeutic value once the deadly cytokine store has been triggered. As explained by James A. Joyce, Chairman and CEO at Aethlon Medican Inc. (OTC BB: AEMD), "Once a cytokine storm has been triggered, the Hemopurifier could serve as the first, and perhaps only option for treating H5N1 infected patients."

To Read "Global Demand Boosts Avian Flu Vaccine Market" In Full Click Here: http://www.China-AsiaStocks.com/Articles/Avian_Flu.asp

About our CAS and BIS Portals:

www.China-AsiaStocks.com and www.BiotechIndustryStocks.com portals within the InvestorIdeas.com content umbrella, offer investors research, news and links to public companies within the China-Asia and Biotechnology sectors. CAS and BIS do not make recommendations, but offer unique free information portals to research news, articles, interviews and a growing list of participating public companies in the China-Asia and biotech industry.

China-AsiaStocks.com includes a comprehensive and growing list of China Asia Stocks: http://www.China-AsiaStocks.com/Companies/China-AsiaStocks/Stocks_List.asp

To visit our China-Asia portal in Chinese click here: http://www.china-asiastocks.com/CAS/

Featured Sponsor Participating in the China Asia Market: (CAS is compensated by Bridgetech Holding International as disclosed in disclaimer.)

Bridgetech Holdings International Inc (OTC: BGTH) a leading distributor of western-based healthcare products and medical technology in China. For more info: http://www.china-asiastocks.com/CO/BGTH/Default.asp or visit the company's website at www.bthi.com.

Investorideas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by its "featured companies." Bridgetech Holdings International, Inc five thousand dollars per month and ten thousand shares of 144 stock as a one time fee .Additionally , Aethlon Medical was a former featured company on Investorideas.com, please review previous clients disclaimer.

For More Information Contact:
Dawn Van Zant
800-665-0411
Email: Email Contact
Fei Wang
866-948-0848
Email: Email Contact
Web Site: www.InvestorIdeas.com

[Onthego]

LOR-T NR today 173m at .365

Lorus describes anti-cancer effects of two programs


2006-04-03 08:34 ET - News Release

Ms. Grace Tse reports

SMALL MOLECULE SERIES AND INTERLEUKIN-17E SHOW POTENT ANTICANCER ACTIVITY

Lorus Therapeutics Inc. has released data showing novel anti-cancer activity from two of its lead preclinical programs.

"Lorus is a leader in the development of drug candidates from a broad range of technologies, and our in-house research facility allows us to advance new lead compounds efficiently from discovery to formal drug development, adding significantly to the value of Lorus's drug pipeline. These presentations describing novel agents with strong anti-cancer properties are excellent examples of this strategy at work," said Lorus chief executive officer Dr. Jim Wright.

Series of small molecules suppress tumour cell growth

In a presentation entitled "Novel series of small molecules suppress in vitro and in vivo tumour cell growth of colon carcinoma cells through the induction of Kruppel-like factor 4 (KLF4)," Lorus provides data regarding a series of compounds (2-indolyl imidazol 4, 5-d phenanthroline derivatives) developed by Lorus that demonstrate potent and novel anti-cancer activity. The studies presented describe the characterization of the anti-cancer activity and molecular mechanism of action of these compounds. A pattern of tumour-type selectivity was shown in an in vitro anti-tumour screen at the National Cancer Institute (NCI) developmental therapeutics program, and lead compounds showed potent as well as selective growth inhibition of colon cancer, leukemia, non-small-cell lung cancer and prostate cancer. The compounds exhibited in vivo activity in both the hollow-fibre assay, and in mouse models of human colon and lung tumour growth. In addition, dose-schedule studies defined effective therapeutic dose ranges with no signs of apparent toxicity.

The studies on the mechanisms of action focused on changes in gene expression in response to treatment in human tumour tissue implanted into mice. Results indicate that the compounds target the metal-responsive transcription factor-1 or MTF1, a zinc-dependent protein that modulates expression of genes involved in zinc homeostasis. Drug-mediated displacement of zinc associated with MTF-1 resulted in MTF-1 downregulation leading to a strong induction of the tumour suppressor Kruppel-like factor No. 4 (KLF4), a transcription factor with an emerging role in the development and progression of colon carcinoma as well as other types of cancers. KLF4 is a negative regulator of cell growth through mechanisms that include suppression of cyclin D1 expression, leading to cell cycle arrest at the G1 phase. Critical involvement of KLF4 has been validated in siRNA-mediated knockdown experiments, in which KLF4 downregulation resulted in the loss of drug-mediated cell growth inhibition.

IL-17E demonstrates significant anti-tumour activity

In a presentation entitled "IL-17E, a proinflammatory cytokine, has a novel anti-tumour function in vivo," Lorus examines the role of IL-17E as an anti-tumour agent, a previously unrecognized function of IL-17E.

IL-17E belongs to a larger family of cytokines (proteins that function as part of the immune system) and has potent inflammatory effects in vitro and in vivo. Expression of high levels of IL-17E in mice results in a T helper-2 (TH2) type of immune response, characterized by the expansion of eosinophils, and upregulation of specific TH2 type cytokines including IL-5, IL-4 and IL-13.

IL-17E demonstrated significant anti-tumour activity against a variety of human tumours, including melanoma, pancreatic, colon, lung and ovarian tumours grown in mice. In addition, combinations of IL-17E with chemotherapeutic agents showed enhanced anti-tumour efficacy against human colon, lung, melanoma and ovarian tumour models in mice.

The anti-tumour activity was dose-dependent and was observed using three different routes of administration. Consistent with the observed binding of both human and mouse IL-17E to the mouse IL-17E receptor, human IL-17E also exhibited anti-tumour activity against human tumours grown in mice. Studies on the mechanism of action showed that treatment with IL-17E resulted in increased serum levels of IL-5 and increased percentages of eosinophils in peripheral blood. Spleen cells isolated from IL-17E-treated mice showed increases in eosinophils and B-cells, as well as an increase in the percentage of activated B cells. Furthermore, treatment with IL-17E resulted in phosphorylation of kinases and activation of transcription factors involved in immune stimulation. Taken together, the data support further investigation of the potential clinical application of IL-17E, placing IL-17E in a growing class of anti-cancer immunotherapeutic drugs.

We seek Safe Harbor.

[Onthego]

QLT-T NR today 91m at 8.97

Post says UBC tries to keep the QLTs coming


2006-04-03 07:26 ET - In the News

Also In the News (C-ANP) Angiotech Pharmaceuticals Inc
Also In the News (C-COM) Cardiome Pharma Corp (2)


The Financial Post in its Saturday edition calls the University of British Columbia a spinoff machine. The Post's Jason Kirby writes scores of companies trace their roots to its labs. These include QLT, Angiotech Pharmaceuticals and Cardiome Pharma. At last count, in 2005, the total market cap of the seven largest UBC spinoffs was nearly $6-billion. For the school, which holds patents on technology developed in its labs, that also meant royalty riches. Licensing payments from QLT alone have topped $50-million. But UBC's company spinoff success is at risk of drying up. A combination of skittish venture capitalists and some company flameouts after the tech bubble burst in 2000 is making it difficult for enterprising researchers to raise money and go it alone. Last year, just one new biotech was spun out of UBC. Between 1991 and 2001 there were more than 60. Rather than push companies out the door before they are ready, UBC is in the early stages of developing the quasi-corporate Centre for Drug Research and Development to bridge the gap between academic and business worlds. Companies with promising drugs will get help. Those unlikely to produce marketable drugs will be mercilessly killed off.

[Onthego]

NVAX NR today 8.33

Novavax Bond Holders Elect to Convert $7.0 Million of Outstanding Notes


2006-03-31 07:00 ET - News Release


MALVERN, Pa., March 31 /PRNewswire-FirstCall/ -- Novavax, Inc. , announced today that certain holders of $7.0 million face amount of the company's 4.75% senior convertible notes due July 15, 2009 (the "Notes") exercised their optional conversion right to convert such Notes into 1,294,564 shares of Novavax Common Stock at the per share conversion price of $5.46.

As a result of the conversion, the aggregate principal amount of Notes outstanding will be reduced from $29.0 million to $22.0 million and the company's stockholders' equity will be increased by the same amount. In addition the company's annual interest expense will be reduced by $332,500. With this conversion, the total outstanding shares of Novavax increases to 61.3 million.

About Novavax, Inc.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.

Forward Looking Statements

Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel [phone] or the SEC at http://www.sec.gov .

Novavax, Inc.



CONTACT: Kathy Hamilton, Investor Relations of Novavax Inc.,
[phone], [e-mail]



Web site: http://www.novavax.com/

[Onthego]

DDS-T Sedar annual information posted today

[Onthego]

EMFP NR on the 27/06 at 1.82

Emergency Filtration Products Reports 2005 Financial Results; Company Provides Update on Current NanoMask Filter Production


2006-03-27 12:42 ET - News Release

HENDERSON, Nev. -- (Business Wire) -- March 27, 2006
Company Website: http://www.emergencyfiltration.com

Emergency Filtration Products Inc. (EFP) (OTCBB: EMFP)
today announced financial results for the year ended Dec. 31, 2005.
Revenues for 2005 were $654,872, versus $405,831 for 2004. The company
reported a loss of $1,545,148 ($0.04 per share) for 2005 versus a loss
of $1,605,233 ($0.06 per share) for 2004.
In the fourth quarter of 2005, the company generated revenues of
$534,912, the majority of which were recorded in December as the
company's Henderson facility increased production of its NanoMask
filters. EFP has since opened a second and significantly larger
production facility in Nogales, Mexico, where production of NanoMask
filters -- coating precut filters with contaminant-killing
nanoparticles -- has been underway for a month. EFP is now running two
12-hour shifts, utilizing the Nogales facility on a 24-hour basis,
four days per week. A weekend shift is also planned in the near future
to produce sufficient quantities of NanoMask filters in order to meet
expected demand from large national and international accounts.
"When we first decided to start manufacturing NanoMask filters in
Nogales, we spent a couple of weeks carefully planning the design and
functionality of the facility in order to arrive at the most efficient
operational layout possible, and at the same time, give us maximum
flexibility to rapidly ramp up production," said Douglas K. Beplate,
president and CEO, EFP. "We are producing approximately 100,000
filters during our two 12-hour shifts, four days per week. Our unit
costs are considerably lower in Nogales than at our Henderson
facility. In Henderson, we have recently installed a high-speed
bagging machine that is now operational in an effort to lower costs.
Large orders will be shipped directly from Mexico to our overseas
distributors and smaller orders will be shipped to Henderson for
distribution. Our current manufacturing configuration in Nogales will
allow us to quickly -- within two to three weeks -- ramp up production
to at least three million filters per week if purchase orders
dictate.
"International orders continue to be very strong and we are moving
rapidly to close some large accounts in the United States and
elsewhere," added Beplate. "John Masenheimer, who established our
Nogales facility, has done a terrific job in Mexico, and we expect to
be able to announce a series of large new customers in the near
future."

About the NanoMask

EFP's 2H Nano-Enhanced Environmental Mask, the NanoMask, relies on
the company's core 2H Technology(TM) filtration system, which utilizes
a combination of hydrophobic and hydrophilic filters able to capture
and isolate bacterial and viral microorganisms with efficiencies of
99.9%. The environmental mask utilizes the company's patented 2H
Technology(TM) and nanotechnology to enhance the capture-and-isolation
characteristics of the filter media.

About Emergency Filtration Products
(http://www.emergencyfiltration.com/)

EFP is an air filtration products manufacturer whose patented 2H
Technology(TM) filter system has produced filtration efficiencies of
"greater than 99.99%" at a particulate size of 0.027 microns. Its
initial products were developed for the medical market: the Vapor
Isolation Valve(TM) and RespAide(R) CPR Isolation Mask used for
resuscitation of respiratory/cardiac arrest cases; and the 2H
Breathing Circuit Filter for ventilators, respirators and anesthesia
circuitry. Each has received FDA approval. The company also markets an
Automated External Defibrillator Prep Kit featuring RespAide; and the
NanoMask(R), a nanotechnology enhanced environmental mask. In addition
to filtration products, the company supplies Superstat(R), a modified
hemostatic collagen to the U.S. military for surgery and extreme wound
care.

Safe Harbor Statement

This release may contain statements that are forward looking. Such
statements are made based upon current expectations that are subject
to risk and uncertainty. EFP does not undertake to update
forward-looking statements in this news release to reflect actual
results of and changes in assumptions or changes in other factors
affecting such forward-looking information. The actual future results
of the company could differ significantly from such forward-looking
statements. Sales may be dependent on the success of future marketing
campaigns, the signing of definitive agreements with additional
distributors, and both the perceived need for EFP's products and the
competitive performance of such products in the marketplace.
Contacts:

Emergency Filtration Products Inc.
Douglas K Beplate, 702-558-5164
Fax: [phone]
[e-mail]
www.emergencyfiltration.com
or
Investor Relations
PAN Consultants Ltd.
Philippe Niemetz, 800-477-7570, 212-344-6464
Fax: [phone]
[e-mail]

[Onthego]

AEMD NR today .84

Aethlon Medical and Commonwealth Biotechnologies Sign Cooperative Research Agreement


2006-03-29 07:00 ET - News Release

SAN DIEGO -- (Business Wire) -- March 29, 2006

Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in
developing therapeutic devices for infectious disease, announced today
that it has signed a cooperative research agreement with Commonwealth
Biotechnologies, Inc. (CBI). Under the agreement, Aethlon and CBI will
collaborate to pursue federal grant and research opportunities for the
Aethlon Hemopurifier(TM) within biodefense and pandemic preparedness
programs. Since 1999, Commonwealth researchers have managed or
participated in awarded biodefense grants exceeding $20,000,000 in
value. CBI also operates a secure BSL-3 containment facility able to
receive and work with select agents as defined by the Centers for
Disease Control (CDC).
"In addition to its obvious value as a treatment for acute viral
infections, the Hemopurifier(TM) technology developed by Aethlon has
enormous potential as a device to manage exposure to the viral agents
identified by the CDC and other agencies as biothreat agents. It is
simple in concept, straightforward in design, and has been shown to be
effective in removing and trapping a variety of viruses," said Dr.
Richard J. Freer, Chairman & COO of CBI. "We view this partnership as
a natural to bring technology and expertise together to provide a very
strong package for presentation to the many agencies, including the
Department of Homeland Security, concerned with the threat of
bioterrorism," concluded Dr. Freer.
James A. Joyce, Chairman & CEO of Aethlon, stated: "Our colleagues
at Commonwealth have an established record of securing grant income
related to government sponsored biodefense initiatives." Joyce
concluded: "We look forward to leveraging the resources of both
organizations as a means to advance the commercialization of our
Hemopurifier(TM) as a broad-spectrum treatment against evolving
pandemic and bioweapon threats."

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat
infectious disease. The device, known as the Hemopurifier(TM), is a
broad-spectrum treatment countermeasure against drug and vaccine
resistant bioweapons, naturally evolving pandemic threats such as H5N1
Avian Flu, and chronic infectious disease targets including
Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon
has also initiated research on a second generation Hemopurifier(TM)
that targets the capture of growth factors inherent in the spread of
Cancer. More information on Aethlon Medical and the Hemopurifier(TM)
technology can be found at www.aethlonmedical.com.

About Commonwealth Biotechnologies

Commonwealth Biotechnologies, Inc. is a solutions provider to the
global biotechnology industry, academic institutions, government
agencies, and pharmaceutical companies. It offers broad ranging
expertise and a complete array of the most current analytical and
synthetic chemistries and biophysical analysis technologies, many of
which are not available from other commercial sources. CBI has crafted
a stimulating, open environment where scientists collaborate among
themselves and with its clients, take on interesting challenges and
develop creative solutions. Through its FIL division, CBI offers
comprehensive genetic identity testing, including paternity, forensic,
and CODIS analyses. CBI is accredited by the American Association of
Blood Banks, CLIA, and the National Forensic Science Technology
Council, and operates fully accredited BSL-3 laboratory. For more
information, visit CBI on the web at www.cbi-biotech.com.

Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.
Contacts:

Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800 x302
[e-mail]
or
James A. Joyce, 858-459-7800 x301
[e-mail]

[Onthego]

SSB-T NR today 83m at .54

Stressgen substitutional listing of shares, warrants


2006-03-28 18:26 ET - Substitutional Listing

TSX bulletin 2006-0352

As a result of the recently effected plan of arrangement involving Old Stressgen, its shareholders, optionholders and warrantholders, and 0747128 B.C. Ltd. (a new corporation created for the purpose of implementing the arrangement and renamed Stressgen Biotechnologies Corp. upon completion of the transaction:


each shareholder will receive one New Stressgen common share, 0.105263158 of an Old Stressgen voting share and 0.052631579 of an Old Stressgen non-voting share for each Old Stressgen common share held; and
each warrantholder will receive one New Stressgen warrant and 0.157894738 of an Old Stressgen second warrant for each Old Stressgen warrant held on the same terms as the old Stressgen warrants.

A total of 83,196,154 common shares and 5,304,149 common share purchase warrants of New Stressgen will be listed and posted for trading at the open on Thursday, March 30, 2006, under the trading information set out below, in substitution for the presently listed common shares and common share purchase warrants of Old Stressgen, which will be delisted at that time.


New common share stock symbol: SSB

New common share Cusip No.: 86330W 10 9

New common share trading: Canadian dollars



New warrant symbol: SSB.WT

New warrant Cusip No.: 86330W 11 7

New warrant trading: Canadian dollars



Designated market-maker: Orion Securities Inc.



Other markets: None



Transfer agent and registrar: Computershare Investor Services Inc. at its principal office in Vancouver and Toronto


It is understood that letters of transmittal were mailed to shareholders and warrantholders on or about March 28, 2006, requesting them to deposit their duly completed letter of transmittal together with their Old Stressgen share certificates and warrant certificates to Computershare Investor Services Inc. at its principal offices in Toronto or Vancouver, in order to receive certificates representing New Stressgen common shares, Old Stressgen voting shares, Old Stressgen non-voting shares, New Stressgen warrants and Old Stressgen second warrants, as the case may be, to which they are entitled.

No fractional New Stressgen common shares or Old Stressgen voting shares or Old Stressgen non-voting shares will be issued pursuant to the arrangement. In the event the arrangement results in a shareholder becoming entitled to a fractional share, in lieu of any fractional share, such shareholder will receive the next lowest number of shares. Additionally, no fractional New Stressgen warrants or fractional Old Stressgen second warrants will be issued pursuant to the arrangement and, in lieu of any fractional warrant, such warrantholder shall receive the next lowest number of warrants.

[PerfectSage]

Bruce: Think bubble when you think gnbt. In the short term it went up too fast/bullish now it's popped. I like gnbt and nvax long term. I'll bet eventually both will get up to their 2001 $15 levels.
I'd bet gnbt will never fall lower than yesterday's $2.85 low.
I never average down. Ever!!! Hold gnbt. I expect gnbt will rally back up above $4 now which you may want to sell into but won't break $5 It'll consolidate at these higher price levels for several months before breaking out above $5.

AVII is worth watching. avnt? wtvn? I don't play pennies. See what they say at 3stocks on fire.

Oh yeah about stocks showing up in the nasdaq pre/after market most actives. I have to like the chart too. ie no falling 200 day moving averages.

I've had a stockcharts.com subscription for 3 years. I'm so used to my default charts now that they have a high readiability factor for me now. Some parts of stockcharts are free.
The gallery view charts are free?
http://stockcharts.com/gallery/?gnbt
You can make 2 indicator sharpcharts for free too?

google search for free stockcharts.
http://www.google.ca/search?hl=en&safe=off&q=free+stock+charts&btnG=Search&meta=

[bruce222]

Perfect Sage-Thanks Again-4takin time.

Regarding GNBT, I was thrown off by your numbers is all. My son of 15 years has type 1 diabetes, so I've been watching this company before I even started activly trading. (which hasn't been long) Anyway, I bought and now hold it. The stock is really pissing me off. When I looked into it a little deeper, they don't have anything (at the moment) that's making them money. It's all R & D, with future hopes, which is cool, but the investment world will only listen to, "We've almost got it," for so long. Hence why the Bslapping continued yesterday, imo. The company lost a boat load of real money last year. OK, let me digress...thanks for the charts showing support and resistance. I take it the first one is 'Stock Charts' by subscription. Think I might have to get this. The left side vol/price nails support and resistance. Let me know what the best chart service value is. I do design/build remodeling work. I design the plans and do a lot of the work myself, so I learned a long time ago if I'm going to buy a tool, I only want to buy it once (relatively speaking) so I look for the best value. Not price-either high or low, but the best value. If I think the best value is the most expensive, then I buy the most expensive. It is very rare that it's the cheapest, so let me know.

On to more digresstion:
Can you give me your Opinion On These Positions-I know all the disclaimers, I just want your opionion, again, if you have time.
Oh, and no laughing. You can take pleasure in the fact that're you're not in the boat with me.

1) GNBT-About 6% of my portfolio is tied up it this. No laughing! Average cost: $3.82 (it hurts me more than you)
As you say, this thing just keeps getting knocked down like some sadomasochistic freak. Do I average down, and if so, how low will this thing go? Or do I simply cut my losses and move on, or do I just hold?

2) NVAX I don't own, but again because of my son's diabetes have looked into this company. It's moving so fast, and for me with what I have to work with cash wise, it's pricey. Just any thoughts on this would be appreciated. It trades a lot of volume, but when I watch it-it just moves around in a 30 to 50 cent area. Then two days later it's up to the next level. I keep waiting for a pull back, but it doesn't seem to really have given me one to enter on. What's your opionion?

3) last one. AVII. Again, before I stared trading, was just listening to how positive this company looked. I enter at $7.04 about 3 days ago, and it moves directly south. What the hell is that? This stock should take off. If I'm missing something, let me know. I'm not searching for agreement if it isn't what your opionin is. "I want the truth."

Lastly, because this is stupid long, and you probably won't even read this far, but I'll throw another penny at you to look at. Actually, 2 sub-pennies.

1) AVNT - it's been under accumulation for awhile, and is at bottom. (.0026) IMO, if you can pick up some anywhere from .026 to .028, and have a little patience it will run. Last time it ran it went to about .0045. So, imo, get out at .039 to .045 and take the cash and never look back.

2) WTVN - I, belive it or not, imo, can actually say for the first time confidently that this is a no brainer. If you can pick up anywhere from .001 to .0014, it should run soon to .0018, imo.

I know this isn't your game, but I feel like I need to offer back a little of what I know because of how much you've helped me.

I'm checking out the nasdaq next. I love those heat maps.

Thanks Again, Perfect Sage, And Trade Well.

Respectfully,

BruceB

[Onthego]

IEX-T NR today 38m at .495

Inex enters research deal with Alnylam


2006-03-27 08:27 ET - News Release

Mr. Timothy Ruane reports

INEX AND ALNYLAM ANNOUNCE RESEARCH COLLABORATION FOR SYSTEMIC DELIVERY OF RNAI THERAPEUTICS

Inex Pharmaceuticals Corp. has signed an exclusive research collaboration agreement with Alnylam Pharmaceuticals, Inc. to evaluate Alnylam's RNAi therapeutics with Inex's systemic liposomal delivery technology.

The work with Alnylam on the encapsulation and delivery of RNAi therapeutics builds on Inex's expertise in the delivery of oligonucleotides under its targeted immunotherapy platform.

The collaboration will evaluate multiple targets including apolipoprotein B (apoB), a protein involved in cholesterol metabolism. The Inex and Alnylam agreement will build on preliminary data published by Alnylam and its collaborators in Nature, the leading international journal of science, showing that the systemic delivery of an apoB RNAi therapeutic significantly reduced blood cholesterol levels.

Under the terms of the agreement, Alnylam has the option to execute a global exclusive licence for specific RNAi therapeutic targets. The licence agreement would include upfront licence fees, future milestone payments and royalties as the products are commercialized. Alnylam also has the right to expand the option to negotiate licence terms for additional targets.

The exercise of the licence option is dependent on the successful completion of the research collaboration and the completion of Inex's spinout of its targeted immunotherapy technology into Tekmira Pharmaceuticals Corp. Tekmira would provide the required staff and financing to support the research collaboration and licence agreement.

Timothy M. Ruane, president and chief executive officer of Inex, said that combining Inex's expertise in the systemic delivery of oligonucleotides with Alnylam's leading position in RNAi therapeutics is a perfect fit. "We look forward to building on Alnylam's promising data published in Nature and finalizing the spinout of Tekmira to advance this collaboration to a full licence agreement."

Dr. John Maraganore, PhD, president and chief executive officer of Alnylam Pharmaceuticals, said: "We are enthusiastic about the collaboration with Inex as brings together two companies with leadership positions in their respective fields. We look forward to working with Inex to advance the development of novel systemic RNAi therapeutics."

About Tekmira Pharmaceuticals Corp.

Inex expects to complete the spinout of Tekmira late in the second quarter of 2006 after receiving necessary court and regulatory approvals. Tekmira will focus on advancing Inex's targeted immunotherapy technology and its lead product, INX-0167. The targeted immunotherapy technology is based on the encapsulation of immunostimulatory oligonucleotides in liposomes and combines the immunostimulatory properties of oligonucleotides into a single synthetic particle. Preclinical studies have demonstrated that INX-0167 enhances the number and potency of certain immune cells, including natural killer (NK) cells. The resultant increase in NK cell activity is important for the enhancement of the potency of monoclonal antibodies through a mechanism known as antibody-dependent cell mediated cytotoxicity (ADCC).

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection, which is the leading cause of hospitalization in infants in the United States. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic and Novartis. The company, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany. Alnylam is honored to be the emerging/mid-cap company recipient of the 2006 James D. Watson Helix Award, the biotechnology industry's award for outstanding achievement.

We seek Safe Harbor.

[Onthego]

GNBT NR today 3.18

Generex Biotechnology Announces Successful Equipment & Filling Line Installation for Commencement of Generex Oral-Lyn(TM) Commercial Production


2006-03-27 07:30 ET - News Release

TORONTO -- (MARKET WIRE) -- 03/27/06

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=114646&ProfileId=051205&am...
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, today announced the successful completion of the delivery and installation of a turnkey Generex Oral-lyn(TM) filling operation at the facilities of PharmaBrand, S.A. (www.pharmabrand.com.ec) in Quito, Ecuador. PharmaBrand is the Company's joint venture partner for the commercialization of Generex Oral-lyn in Latin America. Generex Oral-lyn is the Company's proprietary oral insulin spray product which is designed to replace prandial subcutaneous injections of insulin by delivering insulin into the human body via a spray applied to the buccal mucosa using the Company's proprietary RapidMist(TM) device.

A regulatory compliance and quality control team from Generex will attend at the PharmaBrand facilities early next month to assist in the training of PharmaBrand personnel in respect of the operation of the filling equipment. The Company anticipates that the first commercial production run of 50,000 canisters of Generex Oral-lyn will be completed in April, 2006. Prior to the commencement of that production run, PharmaBrand will have completed the training of its sales force in respect of the new diabetes treatment paradigm offered by Generex Oral-lyn's safe, simple, fast, effective, familiar, and pain-free alternative to prandial insulin injections for patients with either Type-1 or Type-2 diabetes.

The Generex team will also undertake an evaluation of the PharmaBrand manufacturing facilities with a view to assessing the prospect of utilizing those facilities for the production of proteins and peptides to support ongoing research and development in respect of the Antigen Express immunotherapeutic vaccines program.

The Company also responded to a story which appeared on an Internet site Friday afternoon that contained factual inaccuracies. The article referred to the Company's "financial struggles." As indicated in the Company's Form 10-Q Quarterly Report for the fiscal quarter ended January 31, 2006, Generex had cash and short-term investments in excess of $21 million as of January 31, 2006. As at the close of business on March 24, 2006, the Company had cash and short-term investments in excess of $41 million, the strongest financial condition in the Company's history.

The article states that "for the past year, Generex hasn't been able to pay off its debt." That statement is false.

The article states that Generex failed to repay two promissory notes and that "[a]s a result the noteholders (sic) were allowed to convert the debt" into shares of common stock. That statement is false. Had the author reviewed the terms of the debt, he would have seen that the conversion entitlements were included in the promissory notes from the outset. The promissory notes were not repaid in cash on the maturity dates in the context of then on-going negotiations in respect of related transactions. The author states that "Generex also agreed to such terms with other lenders." That is another false statement.

The author makes derisive reference to the Company's losses. Generex is a development stage biotechnology corporation; accordingly, its function has been to spend money on research and development activities which expenditures are recorded as losses. He fails to mention that all of the other small biotechnology companies in the article incurred substantial losses for similar reasons. The author is correct, however, when he makes reference to the Company's expectation of receiving revenue from the sale of Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, by August, 2006.

The author states that Generex is "a stock that faces the threat of delisting." That statement is false. On November 15, 2005, the Company announced that it had received written confirmation from the Nasdaq Stock Market that the Company had achieved compliance with the continued listing requirements in accordance with Nasdaq Marketplace Rule 4310(c)(4). At the present time, Generex very comfortably meets all of the Nasdaq Stock Market quantitative continued listing requirements.

The article is correct when it states that the Antigen Express avian flu vaccine is in pre-clinical development (following a pre-IND meeting with the FDA on February 10, 2006) and that the Antigen Express breast cancer vaccine is in Phase 1 human clinical trials (at Walter Reed Army Medical Center).

"We do not seek to discourage critical review; however, we consider that such review should be based on accurate facts," stated Anna Gluskin, Generex's President & Chief Executive Officer. "The Company made its executives available for the author to speak with. Unfortunately, whatever his underlying motives were, he chose to misstate and distort the facts thereby portraying the Company in an unjustifiably negative manner."

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: [phone]
and [phone]

Ed Lewis
CEOcast, Inc.
Phone: [phone]

[Onthego]

GNBT NR today 3.18

Generex Biotechnology Announces Successful Equipment & Filling Line Installation for Commencement of Generex Oral-Lyn(TM) Commercial Production


2006-03-27 07:30 ET - News Release

TORONTO -- (MARKET WIRE) -- 03/27/06

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=114646&ProfileId=051205&am...
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, today announced the successful completion of the delivery and installation of a turnkey Generex Oral-lyn(TM) filling operation at the facilities of PharmaBrand, S.A. (www.pharmabrand.com.ec) in Quito, Ecuador. PharmaBrand is the Company's joint venture partner for the commercialization of Generex Oral-lyn in Latin America. Generex Oral-lyn is the Company's proprietary oral insulin spray product which is designed to replace prandial subcutaneous injections of insulin by delivering insulin into the human body via a spray applied to the buccal mucosa using the Company's proprietary RapidMist(TM) device.

A regulatory compliance and quality control team from Generex will attend at the PharmaBrand facilities early next month to assist in the training of PharmaBrand personnel in respect of the operation of the filling equipment. The Company anticipates that the first commercial production run of 50,000 canisters of Generex Oral-lyn will be completed in April, 2006. Prior to the commencement of that production run, PharmaBrand will have completed the training of its sales force in respect of the new diabetes treatment paradigm offered by Generex Oral-lyn's safe, simple, fast, effective, familiar, and pain-free alternative to prandial insulin injections for patients with either Type-1 or Type-2 diabetes.

The Generex team will also undertake an evaluation of the PharmaBrand manufacturing facilities with a view to assessing the prospect of utilizing those facilities for the production of proteins and peptides to support ongoing research and development in respect of the Antigen Express immunotherapeutic vaccines program.

The Company also responded to a story which appeared on an Internet site Friday afternoon that contained factual inaccuracies. The article referred to the Company's "financial struggles." As indicated in the Company's Form 10-Q Quarterly Report for the fiscal quarter ended January 31, 2006, Generex had cash and short-term investments in excess of $21 million as of January 31, 2006. As at the close of business on March 24, 2006, the Company had cash and short-term investments in excess of $41 million, the strongest financial condition in the Company's history.

The article states that "for the past year, Generex hasn't been able to pay off its debt." That statement is false.

The article states that Generex failed to repay two promissory notes and that "[a]s a result the noteholders (sic) were allowed to convert the debt" into shares of common stock. That statement is false. Had the author reviewed the terms of the debt, he would have seen that the conversion entitlements were included in the promissory notes from the outset. The promissory notes were not repaid in cash on the maturity dates in the context of then on-going negotiations in respect of related transactions. The author states that "Generex also agreed to such terms with other lenders." That is another false statement.

The author makes derisive reference to the Company's losses. Generex is a development stage biotechnology corporation; accordingly, its function has been to spend money on research and development activities which expenditures are recorded as losses. He fails to mention that all of the other small biotechnology companies in the article incurred substantial losses for similar reasons. The author is correct, however, when he makes reference to the Company's expectation of receiving revenue from the sale of Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, by August, 2006.

The author states that Generex is "a stock that faces the threat of delisting." That statement is false. On November 15, 2005, the Company announced that it had received written confirmation from the Nasdaq Stock Market that the Company had achieved compliance with the continued listing requirements in accordance with Nasdaq Marketplace Rule 4310(c)(4). At the present time, Generex very comfortably meets all of the Nasdaq Stock Market quantitative continued listing requirements.

The article is correct when it states that the Antigen Express avian flu vaccine is in pre-clinical development (following a pre-IND meeting with the FDA on February 10, 2006) and that the Antigen Express breast cancer vaccine is in Phase 1 human clinical trials (at Walter Reed Army Medical Center).

"We do not seek to discourage critical review; however, we consider that such review should be based on accurate facts," stated Anna Gluskin, Generex's President & Chief Executive Officer. "The Company made its executives available for the author to speak with. Unfortunately, whatever his underlying motives were, he chose to misstate and distort the facts thereby portraying the Company in an unjustifiably negative manner."

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: [phone]
and [phone]

Ed Lewis
CEOcast, Inc.
Phone: [phone]

[Onthego]

QLT-T NR today 91m at 8.64

Globe says QLT mulls missed opportunities


2006-03-27 09:06 ET - In the News

The Globe and Mail reports in its Saturday edition in the months leading up to QLT's big drug approval in 2000, a debate raged in its Vancouver offices about how to spend the revenue windfall from its Visudyne anti-blindness drug. The Globe's Leonard Zehr writes the big question was whether it should stick with the eye care market and expand, or to take the technology and develop new applications outside of eye care. Chief executive officer Julia Levy was reluctant to turn QLT into an integrated eye care business. Through a spokeswoman, Ms. Levy said the strategy was to "acquire, through in-licensing or acquisitions, new technologies that would enhance the QLT pipeline beyond our in-house competencies." But things did not work out. QLT now finds itself reeling from a series of drug-testing disappointments, a court ruling of patent infringement, executive defections, a disastrous acquisition in 2004 and new competition. After reaching a high of $119 in 2000, it now sits in a crater in the $6-$7 range on the Toronto Stock Exchange. The depressed stock price has even led to rumblings that a group of investors is attempting to put together financing for a leveraged buyout of the company.

[Onthego]

ONC-T NR today 36m at 5.52

Oncolytics receives U.S. patent 7,014,847


2006-03-27 06:41 ET - News Release

Dr. Matt Coffey reports

ONCOLYTICS BIOTECH INC. ANNOUNCES ISSUANCE OF 15TH U.S. PATENT

Oncolytics Biotech Inc. has been granted United States patent 7,014,847, entitled, "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders." The claims describe methods for preventing reovirus recognition by the host immune system, while concurrently or subsequently administering reovirus, resulting in substantial lysis of the proliferating cells.

"The claims in this United States patent allow manipulation of the immune system that may enhance the effectiveness of Reolysin treatment," said Dr. Matt Coffey, chief scientific officer of Oncolytics. "The use of immune modulation with this class of biologic agent is a growing and promising field of research and we are pleased to have secured patent protection for this new treatment modality."

We seek Safe Harbor.

[PerfectSage]

bruce: gnbt is a canadian biopharma that only trades on the nasdaq. It's a birdflu and a diabetes play. ie an effective avian flu vaccine and needle free insulin delivery system because they have an inhaler technology.

I bought it on wednesday at $3.60 and sold it on thursday in the $4.40's when it was starting to have a spectacular intraday crash. It closed at $3.71? on friday and had a nice bitchslapping in afterhours trading on friday.

I like gnbt long term cuz the 2001 high is $20 and I think it will go that high again eventually. Short term gnbt sucks cuz I've never seen a stock that had a super heavy volume down day that didn't take months to break through to higher highs.

I've got lvlt pegged as probably the next nasdaq hot stock. Maybe gigm and xoma too. xoma was hitting brand spanking new 52 week highs on friday.

Go looking at the nasdaq premarket & aftermarket most actives to find the next possible hot stock. If you see a stock there twice it's probably going to be the hot nasdaq stock du jour.

[bruce222]

GNBT-Running Smoothly, but I have a question.

Perfect Sage,

In post #233 you mention $4.+ for GNBT, and getting out around $5.00. Is this traded on the Canadian Market as well as the US? Reason why I ask is because when I pull up the close of gnbt for friday it's around $3.35 on the Nasdaq. (After Hours Number) I'm just curious if my head is you know where, or is there something I'm not understanding, and will I feel like a complete moron when it's explained to me?

As Always. Thanks.
If this message is bordering on stupidity, it will self-destruct 5 seconds after you've read it and be completely erased from you memory.

BruceB

[bruce222]

Thank You Perfect Sage and Onthego. Great Work!
Just wanted to say thanks to both of you for keeping in touch with me, and offering suggestions. Got a simple way I can trade on the Canadian Exchange? I think you were addresssing this with your last comment to me Onthego, but I wasn't sure. Or, let me know what you are watching that might be traded jointly on one the US Markets. Please forgive me if I'm being a pain in the rear with these questions. On the other hand, Perfect Sage has done nothing but offer wise and insightful advice which I have profitted from already. If there's any leg work or mudane tasks that either of you need done, please don't hesitate to drop me a line.

Again, thanks, much thanks.

BruceB